Vitamin D supplementation safely and substantially reduced the rate of moderate/severe COPD exacerbations in patients with baseline 25-hydroxyvitamin D levels
Clinical trials investigating effects of vitamin D supplementation on COPD have shown conflicting results. This new study pooled individual patient data for 469 participants in 3 randomised controlled trials, which were identified through a search for relevant studies published on PubMed, Embase, the Cochrane Central Register of Controlled Trials and Web of Science up to and including 5 October 2017.
The research, led by Queen Mary University of London, found that vitamin D supplementation did not influence the overall rate of moderate/severe COPD exacerbations (adjusted incidence rate ratio [aIRR], 0.94; 95% CI, 0.78-1.13). Vitamin D did not influence the proportion of participants experiencing at least one serious adverse event (adjusted OR, 1.16; 95% CI, 0.76-1.75).
However, prespecified subgroup analysis revealed that protective effects were seen in participants with baseline 25-hydroxyvitamin D levels
Commenting on the findings, lead researcher, Professor Adrian Martineau, said: "Vitamin D supplementation is safe, and it costs just a few pence to supplement a person for a year - so this is a potentially highly cost-effective treatment that could be targeted at those who have low vitamin D levels following routine testing.
"Around a fifth of COPD patients in the United Kingdom - about 240,000 people - have low levels of vitamin D. Reducing risk of attacks in such a large group would have major benefits for patients and for the NHS, since many attacks require costly hospital admission," Professor Martineau said.